Peptide
Endoluten
Endoluten (A-8, pineal gland peptide complex)
A pineal-derived peptide complex from the Khavinson group, considered the flagship of the bioregulator line. Aimed at circadian rhythm, sleep quality, and downstream endocrine balance.
Summary Does Endoluten really improve sleep, aging, or lifespan? Show / hide ↓
Endoluten is a mixture of short protein fragments made from pineal tissue, a small gland in the brain that helps control the body clock. Animal studies from one research group reported 25 to 30% longer median lifespan, fewer tumors, and more regular sleep-related hormone patterns. Small human studies reported better sleep and other health changes, including lower mortality over six years in elderly Russian participants, but these findings have not been independently confirmed. Claims about telomerase, an enzyme involved in maintaining chromosome ends, come mainly from laboratory studies rather than strong human trials. Overall, the evidence is weak and does not show that Endoluten extends human life.
What this means for you: Endoluten has an interesting theory behind it, but reliable human evidence is lacking. It should be viewed as experimental rather than a proven longevity supplement.
weak evidenceEndoluten is positioned as the gold-standard product in the Khavinson bioregulator line. The rationale rests on the pineal gland's role as a master clock: it secretes melatonin at night, communicates with the suprachiasmatic nucleus, and influences downstream hormones (cortisol, growth hormone, sex steroids) via circadian gating. Loss of pineal peptide output with age, in this model, drives a cascade of endocrine drift.
The Saint Petersburg group has published on Endoluten and its synthetic sibling Epitalon since the 1980s. Reported effects in Russian mouse studies include a roughly 25 to 30 percent increase in median lifespan across several strains, delayed onset of spontaneous tumors, restored melatonin rhythm in aged animals, and reduced spontaneous carcinogenesis. Human data from the same group reports improved sleep quality, restored menstrual cyclicity in perimenopausal women, and, in a small controlled trial, reduced mortality over six years in elderly Russian subjects (Khavinson and Morozov, 2003). None of this has been independently replicated in Western industry-neutral trials.
A separate line of work has connected Epitalon (the purified peptide) to modest telomerase activation in human fibroblast cultures, feeding into the idea that pineal peptides may act on cellular senescence markers. This mechanism has not been demonstrated in a placebo-controlled human trial with hard endpoints.
Inside the biohacking community, Endoluten is often used as a foundational once- or twice-yearly cycle, on the theory that stabilizing circadian rhythm indirectly improves everything downstream. Common protocols pair Endoluten with Cerluten (cortex) and Vladonix or Vladinox (thymus) as a starter stack.
Our position: Endoluten sits at Tier 5 for humans. There is a coherent story, decades of Russian-language work, and a strong following. There is essentially no independent, placebo-controlled Western trial evidence, and the Khavinson lifespan claims should be read as a hypothesis rather than a settled result. Users cycle it because it is short-course, low-dose, and reportedly well-tolerated, not because a robust human evidence base has been built.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.